NYMOX Presenting at Torrey Hills Capital Emerging Growth Conference

Rhea-AI Summary

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced its participation in the Torrey Hills Capital Emerging Growth Conference in San Diego this week. The company expressed enthusiasm for networking with high-caliber investors and plans to make additional presentations to the investment community. Nymox specializes in developing therapeutics targeting unmet needs of the aging male population, particularly its lead drug candidate, Fexapotide Triflutate (FT), which has completed Phase 3 trials involving over 1,700 patients and is preparing for approval applications in the U.S. and Europe.

Positive

• Participation in the Torrey Hills Capital Emerging Growth Conference to connect with sophisticated investors.
• Lead drug candidate Fexapotide Triflutate has completed Phase 3 trials with over 1,700 patients.

Negative

• None.

NYMOX Provides Current Update

HASBROUCK HEIGHTS, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to report today that it will be presenting at the Torrey Hills Capital Emerging Growth Conference this week.  The two-day conference is being held in San Diego, California.  

The Company has indicated that it will be making more presentations to the investment community at this time, and it is very pleased to attend this meeting which has a good number of very high caliber individuals and sophisticated investors that participate. 

About Nymox Pharmaceutical Corporation

Nymox Pharmaceutical Corporation specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the rapidly aging male population in developed economies. The Company’s lead drug candidate for benign prostatic hyperplasia (BPH), Fexapotide Triflutate (FT), has completed Phase 3 development in more than 70 clinical centers in the United States, involving more than 1700 patients during the entire clinical development program. Currently, the Company will soon be applying for approval in major economies around the world, including the United States and Europe.

For more information please contact info@nymox.com or 800-936-9669.

Forward Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2020, and its Quarterly Reports.

For Further Information Contact:
Randall Lanham
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com

FAQ

What is the significance of Nymox's participation in the Torrey Hills Capital Emerging Growth Conference?

Nymox's participation allows for networking opportunities with high-caliber investors, which could enhance visibility and support for the company.

What is Fexapotide Triflutate and its current status?

Fexapotide Triflutate is Nymox's lead drug candidate for benign prostatic hyperplasia, having completed Phase 3 trials and soon to apply for regulatory approval.

How many patients were involved in the Fexapotide Phase 3 trials?

The Phase 3 trials for Fexapotide involved over 1,700 patients across more than 70 clinical centers in the U.S.

In which markets is Nymox planning to seek approval for Fexapotide?

Nymox plans to seek approval for Fexapotide in major economies, including the United States and Europe.